Sign in Subscribe
Cancer

Breakthrough in Cancer Gene Therapy: New Study Using Sindbis Virus Platform

Strategic Insights

— 1 min read

Researchers at New York University (NYU) have made significant progress in cancer gene therapy using a Sindbis viral (SV) vector platform. A new study published in the journal Pharmaceuticals has shown promising results in treating pancreatic cancer, a highly immunosuppressive and challenging disease. The study aimed to assess the treatment efficacy of the Sindbis virus platform in combination with an immune co-stimulatory agent, anti-OX40, in reducing tumors and facilitating an influx of immune response cells into the tumor microenvironment.

Key Takeaways:

  • The Sindbis virus platform has been developed as a treatment for several types of cancers, including pancreatic cancer.
  • The study used orthotopic mouse models to generate human pancreatic tumors in mice, which were then treated with Sindbis vectors.
  • The treatment efficacy was assessed using imaging, flow cytometry, multi-immunofluorescence, and elispot analysis.
  • The combination of SV vector expressing IL12 with anti-OX40 was found to reduce tumors, facilitate an influx of immune response cells, and prevent tumors in mice rechallenged with tumor cells.
  • The study concluded that the Sindbis virus platform provides an oncolytic-virus-mediated and immunotherapeutic strategy to overcome the challenging microenvironment of pancreatic cancer.
  • The research was supported by the National Institutes of Health (NIH) and the Experimental Pathology Research Laboratory at NYU Langone Medical Center.

Statistics:

  • The study used three mouse model systems to assess the treatment efficacy of the Sindbis virus platform.
  • Imaging of tumors was performed using MRI or in vivo imaging using luciferase.
  • Flow cytometry, multi-immunofluorescence, and elispot analysis were performed on certain tumors to assess the immune response.
  • The combination of SV vector expressing IL12 with anti-OX40 reduced tumors by xxx% in mice.
  • The treatment prevented tumors in mice rechallenged with tumor cells, with a success rate of xxx%.

Sources:

  • Sindbis Virus Platform Provides an Oncolytic-Virus-Mediated and Immunotherapeutic Strategy to Overcome the Challenging Microenvironment of Pancreatic Cancer. Pharmaceuticals, 2025, 18(5), 725.
  • https://doi.org/10.3390/ph18050725 (free version available)

Read more